<DOC>
	<DOC>NCT02907996</DOC>
	<brief_summary>The objectives of this study are to collect and assess data related to safety and effectiveness of Sovaldi treatment regimens, per the approved prescribing information for Sovaldi, in routine clinical practice and report results to Korean Ministry of Food and Drug Safety (MFDS).</brief_summary>
	<brief_title>Evaluate the Safety and Effectiveness of Sovaldi Treatment Regimens in Patients With Chronic Hepatitis C Virus (HCV) Infection in a Korean Real-World Setting</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Key Patients aged 18 years and older who are living in Korea Patients with chronic HCV infection eligible for treatment with Sovaldi as indicated in the approved prescribing information for Sovaldi. Patients who have been informed of all pertinent aspects of the study and have voluntarily signed an informed consent form Key Patients treated with Sovaldi outside of the approved prescribing information for Sovaldi in Korea Patients who have a contraindication (refer to the Korea prescribing information) Patients who have a contraindication to ribavirin or peginterferon alfa or Daklinza Pregnant or breast feeding women Patients who have previously been administered Sovaldi Patients participating in a concurrent HCV clinical trial Patients planning on leaving the country during the study period Note: Other protocol defined Inclusion/Exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>